Related Experiment Video
Updated: Jun 21, 2025

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function
Published on: May 4, 2021
B3galt5 functions as a PXR target gene and regulates obesity and insulin resistance by maintaining intestinal
Jinhang Zhang1, Ya Huang1,2, Hong Li1
1Department of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Abstract:
Pregnane X receptor (PXR) has been reported to regulate glycolipid metabolism. The dysfunction of intestinal barrier contributes to metabolic disorders. However, the role of intestinal PXR in metabolic diseases remains largely unknown. Here, we show that activation of PXR by tributyl citrate (TBC), an intestinal-selective PXR agonist, improves high fat diet (HFD)-induced obesity. The metabolic benefit of intestinal PXR activation is associated with upregulation of β-1,3 galactosyltransferase 5 (B3galt5). Our results reveal that B3galt5 mainly expresses in the intestine and is a direct PXR transcriptional target. B3galt5 knockout exacerbates HFD-induced obesity, insulin resistance and inflammation. Mechanistically, B3galt5 is essential to maintain the integrity of intestinal mucus barrier. B3galt5 ablation impairs the O-glycosylation of mucin2, destabilizes the mucus layer, and increases intestinal permeability. Furthermore, B3galt5 deficiency abolishes the beneficial effect of intestinal PXR activation on metabolic disorders. Our results suggest the intestinal-selective PXR activation regulates B3galt5 expression and maintains metabolic homeostasis, making it a potential therapeutic strategy in obesity.
Insights
Intestinal Pregnane X receptor (PXR) activation improves obesity by upregulating B3GALT5, which maintains gut barrier integrity. This highlights intestinal PXR as a therapeutic target for metabolic homeostasis.
Area of Science:
- Metabolic disease research
- Gastroenterology
- Pharmacology
Background:
- Intestinal barrier dysfunction is linked to metabolic disorders.
- The role of intestinal Pregnane X receptor (PXR) in metabolic diseases is largely unknown.
Purpose of the Study:
- To investigate the role of intestinal PXR in high fat diet (HFD)-induced obesity.
- To explore the therapeutic potential of intestinal PXR activation.
Main Methods:
- Activation of PXR using tributyl citrate (TBC), an intestinal-selective agonist.
- Analysis of B3GALT5 expression and its role in HFD-induced obesity.
- Assessment of intestinal barrier integrity and mucin O-glycosylation.
Main Results:
- Intestinal PXR activation by TBC ameliorates HFD-induced obesity.
- B3GALT5 is a direct PXR target gene crucial for intestinal mucus barrier integrity.
- B3GALT5 deficiency exacerbates obesity, insulin resistance, and inflammation, abolishing TBC's benefits.
Conclusions:
- Intestinal PXR activation improves metabolic homeostasis by upregulating B3GALT5.
- B3GALT5 maintains intestinal barrier function through mucin O-glycosylation.
- Intestinal-selective PXR activation is a potential therapeutic strategy for obesity.
More Related Videos
06:08Author Spotlight: Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator
Published on: May 19, 2023
08:34Mechanism of Regulation of Adipocyte Numbers in Adult Organisms Through Differentiation and Apoptosis Homeostasis
Published on: June 3, 2016
Related Concept Videos
Regulation of Food Intake
Cell Specific Gene Expression
Insulin: The Receptor and Signaling Pathways
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Hormonal Regulation
Glucose Absorption Into the Small Intestine